AAP
VNDA icon

Ardsley Advisory Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Ardsley Advisory Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,000
Closed -$110K – 199
2013
Q3 		$110K Hold
10,000
– – 0.02% 135
2013
Q2 		$81K Buy
+10,000
New +$67.3K 0.02% 127

Other funds holding VNDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ardsley Advisory Partners's VNDA Position: Q4 2013 in Review

Ardsley Advisory Partners sold out of Vanda Pharmaceuticals (VNDA) in Q4 2013, closing a stake of 10,000 shares — an estimated $110K sold.

Ardsley Advisory Partners first reported a position in VNDA in Q2 2013 and held it in 2 quarters. The position peaked at $110K in Q3 2013. 86 funds tracked by Wall St. Rank hold VNDA as of Q4 2013.

  • Ardsley Advisory Partners reported no remaining Vanda Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Ardsley Advisory Partners sold 10,000 Vanda Pharmaceuticals shares in Q4 2013, an estimated $110K.
  • Ardsley Advisory Partners first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Ardsley Advisory Partners's Vanda Pharmaceuticals position peaked at $110K in Q3 2013.
  • 86 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2013.

Based on Ardsley Advisory Partners's 13F filing for Q4 2013, filed 12 Feb 2014.